Susquehanna Fundamental Investments LLC Buys New Position in 10x Genomics, Inc. (NASDAQ:TXG)

Susquehanna Fundamental Investments LLC bought a new position in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 106,788 shares of the company's stock, valued at approximately $1,533,000. Susquehanna Fundamental Investments LLC owned approximately 0.09% of 10x Genomics at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. JPMorgan Chase & Co. raised its holdings in shares of 10x Genomics by 355.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 355,488 shares of the company's stock valued at $8,027,000 after buying an additional 277,355 shares in the last quarter. Entropy Technologies LP boosted its stake in shares of 10x Genomics by 285.6% in the 4th quarter. Entropy Technologies LP now owns 37,595 shares of the company's stock valued at $540,000 after purchasing an additional 27,844 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of 10x Genomics by 209.8% during the 4th quarter. SG Americas Securities LLC now owns 73,046 shares of the company's stock valued at $1,049,000 after purchasing an additional 49,468 shares during the last quarter. Alberta Investment Management Corp purchased a new position in 10x Genomics in the 4th quarter worth $3,206,000. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in 10x Genomics during the 4th quarter valued at about $326,000. 84.68% of the stock is owned by hedge funds and other institutional investors.

10x Genomics Stock Up 4.1 %

TXG stock traded up $0.33 during midday trading on Friday, hitting $8.43. The company's stock had a trading volume of 3,188,259 shares, compared to its average volume of 2,261,416. The firm has a market capitalization of $1.03 billion, a price-to-earnings ratio of -5.55 and a beta of 2.01. 10x Genomics, Inc. has a 12 month low of $6.78 and a 12 month high of $28.25. The company has a 50 day moving average of $9.17 and a two-hundred day moving average of $12.79.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. On average, analysts anticipate that 10x Genomics, Inc. will post -1.43 earnings per share for the current fiscal year.

Insider Buying and Selling at 10x Genomics

In other news, insider Benjamin J. Hindson sold 4,573 shares of the business's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $50,623.11. Following the transaction, the insider now owns 335,324 shares of the company's stock, valued at approximately $3,712,036.68. The trade was a 1.35 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Serge Saxonov sold 5,092 shares of 10x Genomics stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $56,368.44. Following the transaction, the chief executive officer now directly owns 879,482 shares of the company's stock, valued at $9,735,865.74. The trade was a 0.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 10.03% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on TXG shares. Barclays dropped their target price on shares of 10x Genomics from $15.00 to $12.00 and set an "overweight" rating for the company in a research report on Thursday, April 10th. Stifel Nicolaus decreased their price target on shares of 10x Genomics from $21.00 to $18.00 and set a "buy" rating for the company in a research note on Thursday, February 13th. UBS Group lowered their target price on shares of 10x Genomics from $20.00 to $14.00 and set a "neutral" rating for the company in a report on Thursday, February 13th. Citigroup cut their price target on 10x Genomics from $20.00 to $15.00 and set a "buy" rating on the stock in a research note on Tuesday, March 4th. Finally, Canaccord Genuity Group dropped their target price on 10x Genomics from $20.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $18.85.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.